



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Focal Treatments for Prostate Cancer are addressed separately in medical policy 00484.

Note: Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy are addressed separately in medical policy 00045.

Note: Proton Beam Therapy are addressed separately in medical policy 00187.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider whole gland cryoablation of the prostate as treatment of clinically localized (organ-confined) prostate cancer when patient selection criteria are met to be **eligible for coverage**.**

Patient Selection Criteria

Coverage eligibility for whole gland cryoablation of the prostate as treatment of clinically localized (organ-confined) prostate cancer will be considered when any of the following criteria are met:

- As an initial treatment; or
- As salvage treatment of disease that recurs following radiotherapy.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of whole gland cryoablation of the prostate as treatment of clinically localized (organ-confined) prostate cancer when patient selection criteria are not met to be **investigational**.*

Background/Overview

Prostate Cancer

Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of cancer death among men in the U. S., with an estimated 268,490 new cases and 34,500 deaths in 2022. The diagnosis and grading of prostate cancer are performed by taking a biopsy of the prostate gland.

Treatment

Whole gland (also known as total) cryoablation is one of several methods used to treat clinically localized prostate cancer and may be considered an alternative to radical prostatectomy or external-beam radiotherapy (EBRT). Additionally, whole gland cryoablation may be used for salvage of nonmetastatic relapse following initial therapy for clinically localized disease. Using percutaneously inserted cryoprobes, the glandular tissue is rapidly frozen and thawed to cause tissue necrosis. Cryosurgical ablation is less invasive than radical prostatectomy and recovery time may be shorter. External-beam radiotherapy requires multiple treatments, whereas cryoablation usually requires a single treatment.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Cryoablation of prostate cancer is a surgical procedure that uses previously approved and available cryoablation systems; and as a surgical procedure, it is not subject to regulation by the U.S. FDA.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Cryoablation, also known as cryotherapy or cryosurgery, is a procedure that attacks cancer cells using extremely cold gas. This technique can be used to treat prostate cancer by percutaneously inserting thin, needle-like cryoprobes into the prostate gland and then sending very cold gas down the cryoprobes to rapidly freeze and thaw the tissue, causing necrosis. This review evaluates evidence on the use of total (whole gland, definitive therapy) cryoablation.

Summary of Evidence

For individuals who are considering initial treatment for localized prostate cancer who receive whole gland cryoablation, the evidence includes systematic reviews, 2 randomized controlled trials, and many comparative and noncomparative observational studies. Relevant outcomes are overall survival (OS), disease-specific survival, symptoms, functional outcomes, quality of life (QOL), and treatment-related morbidity. High-quality data comparing cryoablation with external-beam radiotherapy (EBRT), radical prostatectomy, or active surveillance are lacking, but available data have suggested similar OS and disease-specific survival rates compared with radical prostatectomy and EBRT. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have salvage treatment for a recurrence of localized prostate cancer following radiotherapy who receive whole gland cryoablation, the evidence primarily includes case series and a few retrospective studies comparing salvage cryoablation with salvage prostatectomy or brachytherapy. Relevant outcomes are OS, disease-specific survival, symptoms, functional outcomes, QOL, and treatment-related morbidity. High-quality data comparing salvage cryoablation with salvage prostatectomy or brachytherapy are lacking, though limited evidence suggests that salvage cryotherapy may be associated with better survival outcomes than prostatectomy. Men with recurrent localized prostate cancer have limited treatment options and prostatectomy can be difficult

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

in tissue that has been irradiated. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information

Input was received from 1 physician specialty society and 4 academic medical centers while this policy was under review in 2009. There was strong agreement that cryoablation should be considered medically necessary as an option in the initial treatment of organ-confined prostate cancer, as well as for use as salvage therapy for disease recurrence after radiotherapy.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

In response to requests, input was received from 1 physician specialty society and 4 academic medical centers while this policy was under review in 2009. There was strong agreement that cryoablation should be considered medically necessary as an option in the initial treatment of organ-confined prostate cancer, as well as for use as salvage therapy for disease recurrence after radiotherapy.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) guidelines (v.4 2022) for prostate cancer indicate cryosurgery and high-intensity focused ultrasound are options for radiotherapy recurrence in patients who have no evidence of metastatic disease. NCCN does not recommend cryotherapy as routine primary therapy for localized prostate cancer due to limited long-term data comparing cryotherapy with radiation or radical prostatectomy.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022
 Original Effective Date: 06/24/2002
 Current Effective Date: 05/08/2023

American Urological Association et al

In 2022, the American Urological Association and the American Society for Radiology Oncology issued a joint, updated guideline on the treatment of clinical localized prostate cancer; the guideline was additionally endorsed by the Society of Urologic Oncology. In the guideline, treatment recommendations are stratified according to risk group, and ablative techniques are discussed in general with no recommendations specific to whole-gland cryoablation (Table 1).

Table 1. Treatment Recommendations Related to Cryoablation by Prostate Cancer Risk Group

Severity/ Risk Group	Risk Definition	Treatment Recommendation	LOE	GOE	Clinical Considerations
Low-risk disease	PSA <10 ng/mL AND Grade Group 1 AND clinical stage T1- T2a	For patients with low- risk prostate cancer, clinician should recommend active su rveillance as the preferred man agement option	Strong	A	The Panel believes that the benefits of aggressive treatment do not outweigh the risk of treatment- related harms for most patients with low-risk disease. The Panel acknowl edges that select patients with low- risk disease may elect definitive local therapy after an informed discussio n between



Louisiana

Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

					clinician and patient.
Intermediate-risk disease	PSA 10- <20 ng/mL OR Grade Group 2-3 OR clinical stage T2b-c	Clinicians should inform patients with intermediate-risk prostate cancer considering whole gland or focal ablation that there are a lack of high-quality data comparing ablation outcomes to radiation therapy, surgery, and active surveillance	Expert opinion	---	<p>The Panel believes that ablation maybe considered in select, appropriately informed patients (with clinical trial enrollment prioritized).</p> <p>Patients considering ablation should be counseled regarding side effects and recurrence risk and should be followed post-ablation with PSA, DRE, MRI, and biopsy tailored to their specific health and cancer characteristics.</p>
High-risk disease	PSA>20 ng/mL OR Grade Group 4-5	Clinicians should not recommend whole gland or focal ablation for patients with high-risk prostate	Expert opinion	---	There is a lack of data supporting treatment of high-risk disease with ablation.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022
Original Effective Date: 06/24/2002
Current Effective Date: 05/08/2023

	OR clinical stageT3	cancer outside of a clinical trial			
--	---------------------	------------------------------------	--	--	--

DRE: digital rectal exam; GOE: grade of evidence; HIFU: high-intensity focused ultrasound; LOE: level of evidence; MRI: magnetic resonance imaging; PSA: prostate-specific antigen.

U.S. Preventive Services Task Force Recommendations

A systematic review of localized prostate cancer treatments was prepared by Fenton et al (2018) for the Agency for Healthcare Research and Quality, updating the 2002 U.S. Preventive Services Task Force recommendation. Reviewers found no studies comparing cryoablation with watchful waiting and no randomized trials or cohort studies evaluating overall survival or prostate cancer-specific mortality outcomes. The available evidence was mostly from uncontrolled studies, found to be very limited, and not sufficiently reliable to estimate the benefits or harms of cryoablation.

Medicare National Coverage

The Centers for Medicare & Medicaid Services have determined that total cryotherapy is medically necessary and appropriate as primary treatment for clinically localized prostate cancer in stages T1 to T3. Salvage cryoablation is only medically necessary and appropriate in localized disease when radiotherapy has failed as primary treatment, and the patient meets 1 of 3 criteria: stage T2B or below, Gleason score less than 9, or prostate-specific antigen level of less than 8 ng/mL. Salvage cryoablation after the failure of other therapies is not covered.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT01727284	Technical Success, Safety, and Short and Long-Term Efficacy for MR-Guided Cryoablation of Prostate Bed Recurrences	100	Dec 2023



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

<i>Unpublished</i>			
NCT01398657	Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy for High-Risk Localized Prostate Cancer - Open-Label Randomized Clinical Study	182	Jun 2016 (Unknown; last updated Nov 2012)
NCT02615223	A Prospective Multi-Center Study to Compare the QOL and Efficacy of Endocrine Therapy with or without Cryoablation for Stage IV Prostate Cancer	120	Dec 2018 (Unknown; last updated Jun 2017)
NCT02605226	A Prospective Multi-Center Study to Compare the QOL and Efficacy of External Beam Radiation Therapy or Cryoablation Therapy for Stage III Prostate Cancer (CRYO-PCA-III)	240	Dec 2018 (Unknown; last updated Jun 2017)
NCT03348722	START (Active Surveillance or Radical Treatment for Newly Diagnosed Patients with a Localized, Low Risk, Prostate Cancer): an Epidemiological Study of the Oncology Network of Piemonte and Valle d'Asosta, Italy	3000	Nov 2019 (Unknown; last updated Nov 2017)

NCT: national clinical trial.

References

1. National Cancer Institute Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: Common Cancer Sites.
2. Gao L, Yang L, Qian S, et al. Cryosurgery would be An Effective Option for Clinically Localized Prostate Cancer: A Meta-analysis and Systematic Review. Sci Rep. Jun 07 2016; 6: 27490. PMID 27271239
3. Chin JL, Ng CK, Touma NJ, et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1): 40-5. PMID 17579613

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

4. Chin JL, Al-Zahrani AA, Autran-Gomez AM, et al. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). *J Urol.* Oct 2012; 188(4): 1170-5. PMID 22901586
5. Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. *Cancer.* Jan 15 2010; 116(2): 323-30. PMID 19937954
6. Ball AJ, Gambill B, Fabrizio MD, et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. *J Endourol.* Oct 2006; 20(10): 723-31. PMID 17094746
7. Elkjaer MC, Borre M. Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: a single-centre experience. *Scand J Urol.* Feb 2014; 48(1): 27-33. PMID 23597178
8. Gould RS. Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: comparison of early results and the role of transurethral resection in cryosurgery. *J Urol.* Nov 1999; 162(5): 1653-7. PMID 10524891
9. Hubosky SG, Fabrizio MD, Schellhammer PF, et al. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. *J Endourol.* Dec 2007; 21(12): 1521-31. PMID 18186694
10. Xiong T, Turner RM, Wei Y, et al. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. *BMJ Open.* May 15 2014; 4(5): e004285. PMID 24833678
11. Robinson JW, Donnelly BJ, Siever JE, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. *Cancer.* Oct 15 2009; 115(20): 4695-704. PMID 19691092
12. Bahn DK, Lee F, Badalament R, et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. *Urology.* Aug 2002; 60(2 Suppl 1): 3-11. PMID 12206842
13. Donnelly BJ, Saliken JC, Ernst DS, et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. *Urology.* Oct 2002; 60(4): 645-9. PMID 12385926
14. Ellis DS. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. *Urology.* Aug 2002; 60(2 Suppl 1): 34-9. PMID 12206846

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

15. Long JP, Bahn D, Lee F, et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. *Urology*. Mar 2001; 57(3): 518-23. PMID 11248631
16. Onik G. Image-guided prostate cryosurgery: state of the art. *Cancer Control*. Nov-Dec 2001; 8(6): 522-31. PMID 11807422
17. Robinson JW, Donnelly BJ, Saliken JC, et al. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. *Urology*. Aug 2002; 60(2 Suppl 1): 12-8. PMID 12206843
18. Aus G, Pileblad E, Hugosson J. Cryosurgical ablation of the prostate: 5-year follow-up of a prospective study. *Eur Urol*. Aug 2002; 42(2): 133-8. PMID 12160583
19. De La Taille A, Benson MC, Bಾಗಿella E, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. *BJU Int*. Feb 2000; 85(3): 281-6. PMID 10671882
20. Han KR, Cohen JK, Miller RJ, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. *J Urol*. Oct 2003; 170(4 Pt 1): 1126-30. PMID 14501706
21. Prepelica KL, Okeke Z, Murphy A, et al. Cryosurgical ablation of the prostate: high risk patient outcomes. *Cancer*. Apr 15 2005; 103(8): 1625-30. PMID 15747374
22. Aus G. Cryosurgery for prostate cancer. *J Urol*. Nov 2008; 180(5): 1882-3. PMID 18801502
23. Lian H, Guo H, Gan W, et al. Cryosurgery as primary treatment for localized prostate cancer. *Int Urol Nephrol*. Dec 2011; 43(4): 1089-94. PMID 21475948
24. Williams SB, Lei Y, Nguyen PL, et al. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. *BJU Int*. Jul 2012; 110(2 Pt 2): E92-8. PMID 22192688
25. Jones JS, Rewcastle JC, Donnelly BJ, et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. *J Urol*. Aug 2008; 180(2): 554-8. PMID 18550117
26. Tay KJ, Polascik TJ, Elshafei A, et al. Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. *J Endourol*. Jan 2016; 30(1): 43-8. PMID 26414656
27. Ramsay CR, Adewuyi TE, Gray J, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*. Jul 2015; 19(49): 1-490. PMID 26140518
28. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. *J Urol*. Jun 2001; 165(6 Pt 1): 1937-41; discussion 1941-2. PMID 11371885

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

29. Robinson JW, Donnelly BJ, Coupland K, et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. *Urol Oncol*. Nov-Dec 2006; 24(6): 472-86. PMID 17138127
30. Mouraviev V, Spiess PE, Jones JS. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. *Eur Urol*. Jun 2012; 61(6): 1204-11. PMID 22421081
31. Peters M, Moman MR, van der Poel HG, et al. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. *World J Urol*. Apr 2013; 31(2): 403-9. PMID 22903773
32. Chin JL, Lavi A, Metcalfe MJ, et al. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. *J Urol*. Sep 2021; 206(3): 646-654. PMID 33908799
33. Wenske S, Quarrier S, Katz AE. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. *Eur Urol*. Jul 2013; 64(1): 1-7. PMID 22840351
34. Williams AK, Martinez CH, Lu C, et al. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. *Eur Urol*. Sep 2011; 60(3): 405-10. PMID 21185115
35. Ng CK, Moussa M, Downey DB, et al. Salvage cryoablation of the prostate: follow up and analysis of predictive factors for outcome. *J Urol*. Oct 2007; 178(4 Pt 1): 1253-7; discussion 1257. PMID 17698104
36. Ismail M, Ahmed S, Kastner C, et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. *BJU Int*. Oct 2007; 100(4): 760-4. PMID 17662081
37. Friedlander DF, Gu X, Prasad SM, et al. Population-based comparative effectiveness of salvage radical prostatectomy vs cryotherapy. *Urology*. Mar 2014; 83(3): 653-7. PMID 24581527
38. National Comprehensive Cancer Network. Prostate Cancer. Version 4.2022. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
39. American Urological Association (AUA). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. 2022; <https://www.auanet.org/documents/Guidelines/PDF/Localized%20Prostate%20Cancer%20Guideline%20050922.pdf>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

40. Fenton JJ, Weyrich, MS, Durbin S, et al. U.S. Preventive Services Task Force. Evidence Summary for Prostate Cancer Screening. <https://www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/prostate-cancer-screening>.
41. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Cryosurgery of Prostate (230.9). 2001; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=123&ncdver=1&bc=AAAAQAAAAAAAA&>.

Policy History

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

- | | |
|------------|---|
| 06/20/2002 | Medical Policy Committee review |
| 06/24/2002 | Managed Care Advisory Council approval. Format revision. No substance change to policy. |
| 08/31/2004 | Medical Director review |
| 09/21/2004 | Medical Policy Committee review. Format revision. No substance change to policy. |
| 09/27/2004 | Managed Care Advisory Council approval |
| 09/07/2005 | Medical Director review |
| 09/20/2005 | Medical Policy Committee review. Format revision. Coverage eligibility unchanged. The following clarification statement was added: "Based on review of available data, the Company considers other uses of cryoablation of the prostate to be investigational." |
| 09/22/2005 | Quality Care Advisory Council approval |
| 07/07/2006 | Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged. |
| 10/04/2006 | Medical Director review |
| 10/18/2006 | Medical Policy Committee approval. Format revision, including addition of information added to FDA and or other governmental regulatory approval. References updated and additional references added. Coverage eligibility unchanged. |
| 11/07/2007 | Medical Director review |
| 11/15/2007 | Medical Policy Committee approval. No change to coverage eligibility. |
| 11/05/2008 | Medical Director review |
| 11/18/2008 | Medical Policy Committee approval. No change to coverage eligibility. Rationale updated. |

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

05/07/2009	Medical Director review
05/20/2009	Medical Policy Committee approval. Revised two criteria bullets in coverage section as follows: <ul style="list-style-type: none">• “As an initial treatment of clinically localized (organ-confined) primary prostate cancer; or• As salvage treatment of recurrent (following radiation therapy) localized prostate cancer.” Added investigational statement as follows, “Based on review of available data, the Company considers subtotal prostate cryoablation in the treatment of prostate cancer to be investigational.*”
06/03/2010	Medical Policy Committee review
06/16/2010	Medical Policy Implementation Committee approval
05/05/2011	Medical Policy Committee review
05/18/2011	Medical Policy Implementation Committee approval. No change.
05/03/2012	Medical Policy Committee review
05/16/2012	Medical Policy Implementation Committee approval. No change to coverage.
06/06/2013	Medical Policy Committee review
06/25/2013	Medical Policy Implementation Committee approval. No change to coverage.
06/05/2014	Medical Policy Committee review
06/18/2014	Medical Policy Implementation Committee approval. No change to coverage. Added FDA section.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
09/03/2015	Medical Policy Committee review
09/23/2015	Medical Policy Implementation Committee approval. No change to coverage.
11/03/2016	Medical Policy Committee review
11/16/2016	Medical Policy Implementation Committee approval. Title change, policy statements adjusted to address whole gland treatment.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
11/02/2017	Medical Policy Committee review
11/15/2017	Medical Policy Implementation Committee approval. No change to coverage.
11/08/2018	Medical Policy Committee review
11/21/2018	Medical Policy Implementation Committee approval. No change to coverage.
11/07/2019	Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

11/13/2019 Medical Policy Implementation Committee approval. No change to coverage.
04/02/2020 Medical Policy Committee review
04/08/2020 Medical Policy Implementation Committee approval. No change to coverage.
04/01/2021 Medical Policy Committee review
04/14/2021 Medical Policy Implementation Committee approval. No change to coverage.
04/07/2022 Medical Policy Committee review
04/13/2022 Medical Policy Implementation Committee approval. No change to coverage.
04/06/2023 Medical Policy Committee review
04/12/2023 Medical Policy Implementation Committee approval. No change to coverage.
Next Scheduled Review Date: 04/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)®, copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	55873
HCPCS	C2618
ICD-10 Diagnosis	All related diagnoses

***Investigational** – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

****Medically Necessary** (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Whole Gland Cryoablation of Prostate Cancer

Policy # 00022

Original Effective Date: 06/24/2002

Current Effective Date: 05/08/2023

- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.